The 24th Annual High Country Nuclear Medicine Conference

Vail Marriott Mountain Resort
Vail, Colorado
February 28 - March 5, 2003
http://www.hcnmc.org

Sponsored by the Education & Research Foundation of the Society of Nuclear Medicine

The twenty-fourth year of promoting professional inter-disciplinary dialogue on diagnostic imaging.
The High Country Nuclear Medicine Conference provides a unique opportunity for professionals representing varied disciplines in diagnostic imaging and therapy to learn about new developments in the field and to interact in an open and informal manner with individuals in practice, in academic environments, in industry, and from regulatory agencies. For 23 years this conference has provided the most current information available on a broad spectrum of topics in sessions designed to pose critical questions on techniques, uses, and recent technological advances in the setting of ongoing developments in healthcare.

The 24th Annual Conference will feature crucial and “cutting edge” topics, pairing concise presentations with in-depth multidisciplinary discussions, which together have made this a unique and highly regarded forum. Each session will feature a single, cohesive subject, and there are no concurrent sessions.

The Fourth Invitational Lecture will be presented by James Fletcher, M.D. His lecture is entitled “The Taste of Wine: Facts and Fancy”. This will be presented at the end of the Monday afternoon session.

This year’s meeting will feature sessions on “Molecular Imaging”, “Quality in Nuclear Cardiology and FDG/PET Imaging”, and “Current and Future Role of Dual Modality Imaging”. The Conference will once again provide a forum for an in-depth discussion of nuclear medicine’s role in therapy, which will focus on new developments and future directions in targeted radiotherapy with particular emphasis on the radioimmunotherapy of lymphoma, prostate cancer and targeted radiotherapy of neuroendocrine tumors. “Heart Failure and Nuclear Cardiology” will highlight patients with heart failure and new techniques designed to provide the clinician with assistance in making difficult management decisions. The “Imaging and Drug Development” session covers the use of imaging in both the non-clinical and clinical settings to aid in the development of therapeutic drugs. All modalities will be discussed with an emphasis on imaging rather than the imaging agent. The necessary characteristics of an imaging method...
required for use in drug development will be discussed. The time and
place to use imaging will be explained together with the strengths and
weaknesses of each imaging modality. New this year will be a debate
format session entitled “Debates in Nuclear Cardiology”. The session
“Advances in Imaging Instrumentation” will focus primarily on
PET/CT, during which important CT performance factors will be
reviewed. A discussion of image registration performed with both
combined machines and software methods will be held. The session
“Current Topics with the Federal Regulatory and Research Agencies”
will address several current issues concerning federal agencies (FDA,
NIH, NCI, CMS, and others). Examples of issues to be discussed
include the primary objectives of the National Institute of Biomedical
Imaging and Bioengineering in developing new radiopharmaceuticals;
and imaging technology; the impact of new “user friendly” dosimetry
tables that may replace MIRD; reimbursement for radiopharmaceuticals;
and a discussion of the merging of part of CBER with CDER at
the FDA. Last year we had a teleconference link with federal regula-
tors in Washington during one of the sessions. We are investigating
the possibility of a video-conference link during the Tuesday morning
session in 2003.

A major emphasis of the meeting is fostering open and informal dis-
cussion; therefore, the dress code is informal and enrollment is limited
to 130 registrants at any one session. If the conference is filled, regis-
trants will be placed on a waiting list as applications are received. The
program runs Saturday through Wednesday morning.

Visit us online
http://www.hcnmc.org
SATURDAY
MARCH 1
cont’d

4:30 PM – 7:30 PM
Molecular Imaging
Moderator: Michael D. Devous, Sr., Ph.D.
This session is under development and the most recent details are available online at http://www.hcnmc.org.
Molecular Imaging in the Post-Genomic Era
TBD
Constructing a Molecular Imaging Department
James W. Fletcher, M.D.
Funding Mechanisms for Molecular Imaging
Gary Hutchins, Ph.D.
Recent Advances in MRI Ligands for Molecular Imaging
TBD
Molecular Imaging Opportunities in Oncology
TBD
Molecular Imaging in Dementia
Michael D. Devous, Sr., Ph.D.

MARCH 3
MONDAY
7:00 AM – 9:30 AM
Quality in Nuclear Cardiology and FDG/PET Oncologic Imaging
Moderators: Ernest V. Garcia, Ph.D. & Andrew Taylor, M.D.
Introduction
Ernest V. Garcia, Ph.D.
Quality of Nuclear Cardiology Studies: Technical Aspects
Edward Ficaro, Ph.D.
Quality of Nuclear Cardiology Studies: Clinical and Training Aspects
Mylan Cohen, M.D.
Quality of Nuclear FDG/PET Oncologic Studies: Technical Aspects
Gary Hutchins, Ph.D.
Quality of Nuclear FDG/PET Oncologic Studies: Clinical and Training Aspects
R. Edward Coleman, M.D.
Overview and Challenges
Andrew Taylor, M.D.
Panel Discussion

4:30 PM – 7:30 PM
Debates In Nuclear Cardiology
Moderators: Robert Hendel, M.D. & Daniel S. Berman, M.D.
Attenuation Correction is the New Standard for SPECT Imaging
Pro - Timothy Bateman, M.D.
Con - Guido Germano, Ph.D.
Tc-99m Agents are Superior to Tl-201 for Myocardial Perfusion Imaging
Pro - Gary Heller, M.D., Ph.D.
Con - Timothy Bateman, M.D.
Risk Assessment Should Be Included in Nuclear Cardiology Reports
Pro - Daniel S. Berman, M.D.
Con - Rory Hachamovitch, M.D.

SUNDAY
MARCH 2

7:00 AM – 9:30 AM
Heart Failure And Nuclear Cardiology
Moderators: Robert Hendel, M.D. & Daniel S. Berman, M.D.
Program Overview
Robert Hendel, M.D.
Assessment with Gated SPECT Imaging
Gary Heller, M.D., Ph.D.
Assessment with PET
Jamshid Maddahi, M.D.
MRI for Viability
TBD
Alternate Imaging Modalities for Heart Failure/Viability
(Fatty Acid, Neurohumoral and Receptor Imaging)
Marcelo Di Carli, M.D.
Viability and the STICH Trial
Daniel S. Berman, M.D.
Panel Discussion
MONDAY
MARCH 3
cont’d

4:30 PM – 7:00 PM
Advances in Imaging Instrumentation
Moderators: Michael Devous, M.D., Ph.D. & Horace Hines, Ph.D.

Clinical Importance of CT Performance Factors
Robert Gould, Sc.D.

Review of Commercial PET/CT Equipment
Horace Hines, Ph.D.

PET/CT Panel Discussion
John Engdahl, Ph.D., Horace Hines, Ph.D. & Phil Vernon

Image Registration - Combined Machines vs. Software Methods
Dennis Nelson, Ph.D.

Advances in Animal PET
Joel Karp, Ph.D.

Advances in MR for Cardiology and Oncology
TBD

7:00 PM – 7:40 PM
Fourth Invitational Lecture:
The Taste of Wine: Facts and Fancy
James Fletcher, M.D.

Break 7:40 PM – 8:00 PM
Buffet Dinner 8:00 PM – 10:00 PM

TUESDAY
MARCH 4
cont’d

4:30 PM – 7:30 PM
Current and Future Role of Dual Modality Imaging
Moderators: James W. Fletcher, M.D. & David Hollnagel, B.S., CNMT

Concurrent Imaging vs. Software Fusion Solutions
Gary Hutchins, Ph.D. & Michael Graham, M.D., Ph.D.

Economics of PET/CT and Stand-Alone PET Systems
Ruth Tesar, CNMT

PET/CT in Radiation Therapy Planning
Jeffrey Yap, Ph.D.

Dual-Modality Imaging – New Challenges to Physician and Technologist Education and Training Programs
Michael Graham, M.D., Ph.D. & Lyn Mehlberg, B.S., CNMT

WEDNESDAY
MARCH 5

7:00 AM – 9:30 AM
Radionuclide Therapy
Moderators: Andrew Taylor, M.D. & Gregory Wiseman, M.D.

The Role of Somatostatin Analogs in the Diagnosis and Treatment of Neuroendocrine Carcinomas; from Biotherapy to Radiotherapy
Larry K. Kvols, M.D.

Radioimmunotherapy (RIT) of Prostate Cancer
Lale Kostakoglu, M.D.

Y-90 RIT for Non-Hodgkin’s Lymphoma
Gregory Wiseman, M.D.

Anti-CD-22 RIT for Non-Hodgkin’s Lymphoma
William A. Wegener, M.D., Ph.D.

I-131 RIT for Non-Hodgkin’s Lymphoma
Richard Wahl, M.D. (invited)

Panel Discussion
2003 Faculty, Organizing and Program Committees

Naomi Alazraki, M.D.‘* Emory University School of Medicine Atlanta, GA
Timothy Bateman, M.D. Kansas City School of Medicine Kansas City, MO
Daniel S. Berman, M.D.‘* Cedars-Sinai Medical Center Los Angeles, CA
Marcelo Di Carli, M.D. Children’s Hospital of Michigan Detroit, MI
Ronald Dei Cas, M.D., FACS CMS Baltimore, MD
Friedrich Cavagna, Ph.D. Bracco S.P.A. Milan, Italy
Mylan Cohen, M.D. Maine Cardiology Associates Portland, ME
R. Edward Coleman, M.D. Duke University Medical Center Durham, NC
Michael D. Devous, Sr., Ph.D.‘* UT Southwestern Medical Center Dallas, TX
John Engdahl, Ph.D. Siemens Medical Systems Hoffman Estates, IL
Jeffery Evelhoch, Ph.D. Pharmacia Corporation St. Louis, MO
Edward Ficaro, Ph.D. University of Michigan Ann Arbor, MI
James W. Fletcher, M.D.‘* Indiana/Purdue University at Indianapolis Indianapolis, IN
Naomi Alazraki, M.D.‘* Emory University School of Medicine Atlanta, GA
Timothy Bateman, M.D. Kansas City School of Medicine Kansas City, MO
Daniel S. Berman, M.D.‘* Cedars-Sinai Medical Center Los Angeles, CA
Marcelo Di Carli, M.D. Children’s Hospital of Michigan Detroit, MI
Ronald Dei Cas, M.D., FACS CMS Baltimore, MD
Friedrich Cavagna, Ph.D. Bracco S.P.A. Milan, Italy
Mylan Cohen, M.D. Maine Cardiology Associates Portland, ME
R. Edward Coleman, M.D. Duke University Medical Center Durham, NC
Michael D. Devous, Sr., Ph.D.‘* UT Southwestern Medical Center Dallas, TX
John Engdahl, Ph.D. Siemens Medical Systems Hoffman Estates, IL
Jeffery Evelhoch, Ph.D. Pharmacia Corporation St. Louis, MO
Edward Ficaro, Ph.D. University of Michigan Ann Arbor, MI
James W. Fletcher, M.D.‘* Indiana/Purdue University at Indianapolis Indianapolis, IN
Susan Galbraith, M.D., Ph.D. Bristol-Myers Squibb Princeton, NJ
Ernest V. Garcia, Ph.D.‘* Emory University School of Medicine Atlanta, GA
Guido Germano, Ph.D. Cedars Sinai Medical Center Los Angeles, CA
Robert Gould, Sc.D. University of California, San Francisco San Francisco, CA
Michael Graham, M.D., Ph.D. University of Iowa Iowa City, IA
Rory Hachamovitch, M.D. University of Southern California San Francisco, CA
Gary Heller, M.D., Ph.D. Hartford Hospital Hartford, CT
Robert Hendel, M.D.‘* Rush Presbyterian St. Luke’s Med Center Chicago, IL
Horace Hines, Ph.D.‘* Philips Nuclear Medicine Milpitas, CA
David M. Hollnagel, B.S., CNMT‘+ Ledford Medical Milwaukee, WI
Gary Hutchins, Ph.D. Indiana University Indianapolis, IN
David Israel, M.D., Ph.D. Dana Farber Cancer Institute Boston, MA
Lale Kostakoglu, M.D. Cornell Medical Center New York, NY
Joel Karp, Ph.D. University of Pennsylvania Philadelphia, PA
Larry K. Kvols, M.D. H. Lee Moffitt Cancer Center and Research Institute Tampa, FL
James E. Lamb, Ph.D.‘ GammaPlus, LLC Knoxville, TN
Patricia Love, M.D. CDER-FDA Bethesda, MD
Jamshid Maddahi, M.D. UCLA School of Medicine Los Angeles, CA
Lyn Mehilberg, B.S., CNMT, FSNMT St. Luke’s Medical Center Milwaukee, WI
George Mills, M.D. CBER-FDA Bethesda, MD
Randall E. Millikan, M.D., Ph.D. M.D. Anderson Cancer Center Houston, TX
Dennis Nelson, Ph.D. University Hospitals, Cleveland Cleveland, OH
Adrian Nunn, Ph.D.‘* Bracco Research USA, Inc. Princeton, NJ
Roderic I. Pettigrew, M.D., Ph.D. National Institute of Biomedical Imaging and Bioengineering Bethesda, MD
Carl Seidel, M.S.‘* CWS & Associates Nashua, NH
James E. Smith, Ph.D.‘ JES Consulting Harpswell, ME
Michael Stabin, Ph.D. Vanderbilt University Nashville, TN
Dan Sullivan, M.D. NCI NIH Bethesda, MD
Andrew Taylor, M.D.‘* Emory University School of Medicine Atlanta, GA
Ruth Tesar, CNMT PETNET Pharmaceutical Services Sacramento, CA
Thomas Verdon, M.D.‘ Conifer, CO
Phil Vernon GE Medical Systems Milwaukee, MN
Richard Wahl, M.D. Johns Hopkins Baltimore, MD
William A. Wegener, M.D., Ph.D. Immunomedics, Inc. Morris Plains, N.J.
Gregory Wiseman, M.D.‘* Mayo Clinic Rochester, MN
Jeffrey Yap, Ph.D. Presbyterian University Hospital Pittsburgh, PA

* Organizing Committee
+ Program Committee
Conference Fees
A $550 registration fee is required by January 31, 2003. After that date, an additional $75 will be charged. Daily registration fee is $250. Cancellations allowed if received on or before January 31, 2003, with an administrative fee of $55. Registrations that cannot be accommodated due to space restrictions will be returned without penalty.

Registration includes a reception from 6-8:30 pm on Friday to which spouses, friends and children are invited without additional charge. A buffet dinner for registrants follows the Monday afternoon session and guests are welcome to attend for an additional fee. Food and beverages at all scientific sessions are included in the registration fee for conference registrants only (no family or friends).

Complete the section on “Attendance” on the registration form as this information will be used in ordering the quantity of food and beverage for each session.

Information on recreation opportunities in Vail, including skiing, will be available on the conference web site (www.hcnmc.org).

Accommodations
The Vail Marriott Mountain Resort & Spa is located at 715 West Lionshead Circle, Vail, Colorado 81657. The west wing was completely renovated following the fire in 2000. The remaining rooms in the central and east sections have recently been rebuilt to match those in the west wing. The building exterior, entrance and lobby have also been renovated. The free Vail bus stops at the front door.

To make reservations for Lodge rooms during the dates of the conference, you can book these on-line by going to www.marriott.com/whrcn. For all other reservations, call (800) 648-0720 between 8:00 am - 4:30 pm (M-F). Use the conference code HCNHCNB to receive the group rate.

Reservations must be received no later than Friday, January 31, 2003.

Rates:

- Lodge Room: $275
- Studio Room: $479
- One Bedroom Condo: $511
- Timberline Condo: $767

All above rates subject to applicable state and local taxes.

Please Note: Upon making a room reservation, a deposit equal to two nights rental is required. The remainder of the room charges, as reserved, will be due, in full, 30 days prior to arrival. If a cancellation occurs within 30 days of arrival, the full amount of anticipated room revenue that was billed to the credit card or sent by check will be forfeited. In the event of a verified serious illness or death in the immediate family, all deposits will be refunded.

Transportation
The Vail Valley Tourism & Convention Bureau is offering discounts on combined air/ground transportation packages. Visit www.visitvailvalley.com and follow directions to reach Transportation. Call (800) 525-3875 to request a price quote. You must request both air and ground together to receive the discount.

Vail/Eagle Airport is closest (about 30 miles west of Vail), but flights are limited. Alternatively, Denver International Airport is about 115 miles east of Vail. Ground transportation is readily available at both airports.

Within Vail, a free bus system operates on a frequent basis between 6:00 am – 2:00 am. Other buses make frequent daily runs between Vail Village, Avon, and Beaver Creek for a nominal fee. Rental cars are generally not needed.

Acute Mountain Sickness
Acute mountain sickness (AMS) is the most common form of illness associated with a rapid ascent to altitudes exceeding 7,000-8,000 feet (Vail is located at an altitude of 8,150 feet). Symptoms include shortness of breath with mild exertion, headache, lassitude, loss of appetite, insomnia and even nausea or vomiting. AMS typically resolves spontaneously in 2-4 days; headache can be treated with aspirin, acetaminophen (Tylenol) or ibuprofen. Good hydration coupled with avoidance of alcohol and strenuous exercise for 1-2 days after arriving at a high elevation will minimize the risk of developing AMS. AMS can also be prevented by Diamox (acetazolamide) 125 mg twice a day beginning 24 hours before ascent and continuing for 2-3 days after arrival at the higher elevation. Diamox is a prescription drug; it is a diuretic, will cause increased urination and may cause numbness or tingling in the fingers, toes or around the mouth. Diamox is contraindicated in those allergic to sulfa drugs.

Address questions to Conference Organizer:
Harold O’Brien, Ph.D.
107 La Senda Road
Los Alamos, NM 87544
Phone: (505) 672-3577
Fax: (505) 672-1685
e-mail: hobrien@att.net

Please make conference fee checks payable to:
High Country Nuclear Medicine Conference
(US currency only, no credit cards accepted)
To Register for the 24th Annual High Country Nuclear Medicine Conference:

• Fill out the registration form

• Mail registration form and conference fees to:
  Harold O'Brien, Ph.D.  Phone: (505) 672-3577
  107 La Senda Road  Fax: (505) 672-1685
  Los Alamos, NM 87544  E-mail: hobrien@att.net

Make checks payable to:
High Country Nuclear Medicine Conference
(US currency only; no credit cards accepted)

Visit http://www.hcnmc.org
for information about Vail, Colorado and the Vail Marriott Mountain Resort.

Registration Information

Registration Form

The 24th Annual High Country Nuclear Medicine Conference
February 28 - March 5, 2003

Name:_____________________________________ Degree:_____________
Institution:_______________________________________________________
Address:_________________________________________________________
City:__________________________  State:___________  Zip:_____________
Telephone:_____________________  Fax:_____________________________
E-mail:__________________________________________________________

ATTENDANCE: (Conference Registrants: please check all sessions/functions you will attend)

❑ Friday evening reception  ❑ Monday afternoon
❑ Saturday morning  ❑ Monday buffet
❑ Saturday afternoon  ❑ Tuesday morning
❑ Sunday morning  ❑ Tuesday afternoon
❑ Sunday afternoon  ❑ Wednesday morning
❑ Monday morning

GUESTS ATTENDING: (Other than registrant)
Reception:         Adults________  Children________
Monday Buffet:  Adults________  Children________

CONFERENCE FEES:
I have enclosed a check for the following amount:

❑ $550 — On/before January 31, 2003
❑ $625 — After January 31, 2003
❑ $250 — Daily Registration Fee

Make checks payable to: High Country Nuclear Medicine Conference
(US currency only; no credit cards accepted)

MAIL REGISTRATION FORM AND PAYMENT TO:
Harold O'Brien, Ph.D.  Phone: (505) 672-3577
107 La Senda Road  Fax: (505) 672-1685
Los Alamos, NM 87544  E-mail: hobrien@att.net

Cancellation allowed if received on or before January 31, 2003. Cancellation fee: $55.